Industry session details will be announced in early March. Until then, this page offers a preview of the schedule to help you plan a valuable and engaging industry session experience at the Annual Meeting!
AAPP 2026 industry supported showcases (non-continuing education) are programs developed for educational purposes, designed for the psychiatric pharmacist, and are included in participant registration fees.
A few reminders to attendees:
- Badge scanning:
- Your badge may be scanned upon entry. The scan only captures name, credentials, city, and state.
- Noise courtesy:
- We appreciate you keeping noise to a minimum during sessions.
- Recording notice:
- All events are live-streamed and recorded.
- Seating guidance:
- Fill the room from front to back.
- Do not sit at tables with reserved signs.
- Meal information:
- All industry events feature a meal or refreshment break served 15 minutes before the session start time, inside or directly outside of Regency Ballroom (Level 2).
- Meals are limited and will be served at tables only.
- A limited number of vegetarian/vegan/gluten-free meals are available. If desired, please inform the server upon taking a seat.
- To minimize noise, plates will not be removed after programming begins.
Sunday Program |
Industry Showcase
Lunch will be served from 11:00-11:15 AM Pacific, immediately before the program.
Supported by
 | Monday Programs |
Tardive Dyskinesia: Considerations in the Specialty Pharmacy Setting
Breakfast will be served from 7:00-7:15 AM Pacific, immediately before the program.
Learn More and Register
Overview: This presentation will review TD treatment approaches, highlighting the crucial differences between appropriate treatment and the common, yet inappropriate, use of anticholinergics for TD, and emphasizing considerations for patients taking multiple medications. The role of AUSTEDO XR, an FDA-approved treatment option, will also be reviewed, with a focus on its metabolic profile which allows for few restrictions related to drug-drug interactions.
Learning Objectives
- Review TD treatment approaches
- Highlight differences between appropriate and common use of anticholinergics
- Review role of AUSTEDO XR metabolic profile
Faculty
 | Hany Mohamed, PharmD, RPh, BCGP, BCPP Director of Clinical Services, LI Script LLC Key Opinion Leader and LTC Pharmacy Consultant |
Supported by
Industry Showcase
Lunch will be served from 11:00-11:15 AM Pacific, immediately before the program.
Supported by
The Role of UZEDY in Schizophrenia Treatment: A Clinical Perspective
Refreshment break will be served from 4:30-4:50 PM Pacific, immediately before the program and to permit time for attendees to navigate from prior programming sessions to the Regency Ballroom (Level2).
Learn More and Register
Overview: This presentation will delve into the potential consequences of schizophrenia relapse and highlight the role of long-acting injectables in schizophrenia treatment. Attendees will gain insight into the potential clinical impact of UZEDY through select clinical trial data. Additionally, the session will enhance understanding of the features of UZEDY and its potential role in schizophrenia treatment.
Learning Objectives
- Review potential consequences of schizophrenia relapse
- Highlight the role of long-acting injectables in schizophrenia treatment
- Provide insight to the potential clinical impact of UZEDY through clinical trial data
Faculty
 | Jacob Hanaie, PharmD, APh, BCPP Adjunct Assistant Professor, Keck School of Medicine of the University of Southern California Preceptor, Keck School of Medicine of the University of Southern California Director of Pharmacy, Kedren Acute Psychiatric Hospital |
Supported by
Tuesday Program |
Industry Showcase
Lunch will be served from 11:00-11:15 AM Pacific, immediately before the program.
Supported by
